All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
  Â
Everotas 0.25mg Tablet
Prescription Required
Salt Composition : Everolimus
Manufacturer : INTAS PHARMACEUTICALS LTD
Origin of Medicine : India
10 Tablet(s) In A Strip
Introduction to Everotas 0.25mg Tablet
Everotas 0.25mg tablet is an antineoplastic drug belonging to the class of mTOR kinase inhibitors, containing the active ingredient everolimus. It is used to treat advanced breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumours, and also in the treatment of subependymal giant cell astrocytoma (tumours are found in the ventricles of the brain). Good oral hygiene and regular dental check-ups are important during the treatment since this medicine can cause sores or ulcers in the mouth. It is often combined with cyclophosphamide, an alkylating agent, to treat subependymal giant cell astrocytoma.Â
Before taking this medicine, it is necessary to know that your risk of getting bacterial or viral infection increases with this treatment. If you have been infected with Hepatitis B, Everotas 0.25mg tablet increases the chances of reinfection. Tell your healthcare provider if you experience fever, chills, cough, yellowing of the skin, joint pain, or swelling during this treatment. You must limit your exposure to sunlight and UV light by wearing protective clothing and applying sunscreen frequently, as this medicine may increase the risk of developing cancers. Avoid taking grapefruit juice or grapefruit while taking this medicine.Â
This tablet is not recommended for adolescents and children under the age of 18. Contact your doctor immediately if you experience shortness of breath, chest pain, or worsening cough. During the Everotas 0.25mg tablet treatment, your doctor may periodically monitor your white blood cell counts, platelets, blood sugar, electrolytes, and kidney parameters to prevent serious complications. This medicine has the potential to cause kidney problems. Report to your doctor if you have been diagnosed with liver disorders, heart failure, high blood cholesterol levels, or hypertension before starting this treatment. Avoid live vaccines and close contact with those who have received live vaccines.
Uses of Everotas 0.25mg Tablet
- Advanced breast cancer
- Advanced renal cell carcinoma
- Advanced pancreatic neuroendocrine tumours
- Treatment of subependymal giant cell astrocytoma
Therapeutic Effects of Everotas 0.25mg Tablet
Everotas 0.25mg tablet inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein and helps to reduce the size of tumours and improve outcomes in patients.
Interaction of Everotas 0.25mg Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Everotas 0.25mg tablet and reduce effectiveness by causing undesirable side effects.Â
More Information about Everotas 0.25mg Tablet
- Store Everotas 0.25mg tablet in the original package at room temperature (20°C to 25°C).
- Keep it out of reach from children.
How to consume Everotas 0.25mg Tablet
Take the Everotas 0.25mg tablet as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.
Safety Advices for Everotas 0.25mg Tablet
 Â
Pregnancy
 Â
Everotas 0.25mg tablet is not recommended for pregnant women as it may cause fetal harm. Consult your doctor if you are pregnant or planning for pregnancy during the treatment.
 Â
Breast Feeding
 ÂEverotas 0.25mg tablet passes into your breast milk and harms your baby. It is unsafe to consume this tablet.
 Â
Lungs
 Â
It is not known whether Everotas 0.25mg tablet can be used for patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
 Â
Liver
  Inform your doctor if you have any liver problems before taking Everotas 0.25mg tablet. Regular monitoring of liver function tests is recommended.
 Â
Alcohol
 ÂConsuming alcohol may affect the effectiveness of Everotas 0.25mg tablet. Stop consuming alcohol if you are taking this medicine.
 Â
Driving
  It is unsafe to drive vehicles or operate heavy machinery after taking Everotas 0.25mg tablet, it may cause dizziness and impair your concentration.
Side Effects of Everotas 0.25mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Serious
- Difficulty breathing, or swallowing
- Swelling of face, lips, tongue, throat
- Severe itching, red rash, raised bumps
Common
- Infection (chills, increased temperature)
- Coughing
- Wheezing
- Excessive thirst
- High urine output or severely decreased urine output
- Tiredness
- Bleeding
- Increased appetite with weight loss
Word of Advice
Everotas 0.25mg tablet have the tendency to cause harm to the unborn foetus. Inform your healthcare provider before starting this treatment if you are pregnant, or planning for pregnancy. Your healthcare provider will conduct a pregnancy test before you start treatment with this drug. Discuss effective birth control methods with your healthcare provider and use them during the treatment for 8 weeks after your last dose. This medicine passes into breast milk. Hence, it is not recommended to breastfeed during this treatment. The occurrence of mouth ulcers or sores is pretty common during this treatment, so your healthcare provider will prescribe a mouthwash. Use the mouthwash as recommended which helps prevent and manage the symptoms.
FAQs
Q 1. What you should know before taking Everotas 0.25mg tablet?
Before taking Everotas 0.25mg tablet, it is important to know that your risk of getting bacterial or viral infection increases with this treatment. If you have been infected with Hepatitis B, this drug increases the chances of reinfection. Tell your healthcare provider if you experience fever, chills, cough, yellowing of the skin, joint pain, or swelling during this treatment.
Q 2. Is it safe to use Everotas 0.25mg tablet during pregnancy?
Everotas 0.25mg tablet have the tendency to cause harm to the unborn fetus. Inform your healthcare provider before starting this treatment if you are pregnant, or planning for pregnancy. Your healthcare provider will conduct a pregnancy test before you start treatment with this drug.
Q 3. What are the side effects of Everotas 0.25mg Tablet?
The common side effects that are likely to occur while you are on the treatment with Everotas 0.25mg tablet are fever, chills, skin rash, joint pain, swelling, tiredness, loss of appetite, high risk of infection, mouth ulcers, and difficulty breathing.
Q 4. Is it safe to undergo surgery while on treatment with Everotas 0.25mg tablet?
Everotas 0.25mg tablet may lead to poor wound healing ability. Consult your healthcare provider and stop taking this tablet at least one week before planned surgery.
Q 5. Can I drink alcohol while taking Everotas 0.25mg tablet?
It is generally recommended to avoid drinking alcohol while taking Everotas 0.25mg tablet, as alcohol can increase the risk of liver damage.
Fact Box of Everotas 0.25mg Tablet
Molecule name: Everolimus | Therapeutic class: Antineoplastics |
Pharmacological class: mTOR kinase inhibitors | Indications:Â 1. Advanced breast cancer 2. Advanced renal cell carcinoma 3. Advanced pancreatic neuroendocrine tumors 4. Treatment of subependymal giant cell astrocytoma |
References
- Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on June 2022] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.6658.pdf
- Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
- Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines, 12th edition, 2011, 1743.
- KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
